Swedish Orphan Biovitrum Stock Short Ratio

The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.

Based on the latest financial disclosure, Swedish Orphan Biovitrum has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Drug Manufacturers - Specialty & Generic industry. The short ratio for all Sweden stocks is 100.0% higher than that of the company.

The Macroaxis Fundamental Analysis modules help investors analyze Swedish Orphan Biovitrum's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Swedish Orphan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Swedish Orphan Biovitrum based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.